Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build

Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions

Example Bundle: ePI document Bundle for jentadueto Package Leaflet for language en

Composition category:



Full name:


Authorised dose form:

Legal status of supply:

Domain:

Resource status:


Product classification:

Document Details

Generated Narrative: Bundle TEST PURPOSES ONLY - jentadueto


Document Subject

Generated Narrative: MedicinalProductDefinition mpdea6bb992c7a311f66506a0f31878b7e

identifier: http://ema.europa.eu/identifier/EU/1/12/780/001 (10 x 1 film-coated tablets)

type: Medicinal Product

domain: Human use

status: active

legalStatusOfSupply: Medicinal product subject to medical prescription

name

productName: Jentadueto 2.5 mg/850 mg film-coated tablets

type: Full name

part

part: nan

type: Invented name part

part

part: nan

type: Scientific name part

part

part: nan

type: Strength part

part

part: nan

type: Pharmaceutical dose form part

Usages

-CountryJurisdictionLanguage
*EUEUen

Document Content

Generated Narrative: Composition composition-en-dea6bb992c7a311f66506a0f31878b7e

Language: en

Profile: Composition (ePI)

identifier: http://ema.europa.eu/identifier/EU/1/12/780/001 (10 x 1 film-coated tablets)

status: Final

type: Package Leaflet

category: Raw

date: 2022-02-16 13:28:17+0000

author: Organization ACME industry

title: TEST PURPOSES ONLY - jentadueto

Attesters

-ModeTime
*Official2022-02-16 13:28:17+0000

B. Package Leaflet

unavailable

Package leaflet: Information for the user

What is in this leaflet

What is in this leaflet:

  1. What Jentadueto is and what it is used for
  2. What you need to know before you take Jentadueto
  3. How to take Jentadueto
  4. Possible side effects
  5. How to store Jentadueto
  6. Contents of the pack and other information

1. What jentadueto is and what it is used for

The name of your tablet is Jentadueto. It contains two different active substances linagliptin and metformin.

Linagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors).

Metformin belongs to a class of medicines called biguanides. How Jentadueto works The two active substances work together to control blood sugar levels in adult patients with a form of diabetes called type 2 diabetes mellitus . Along with diet and exercise, this medicine helps to improve the levels and effects of insulin after a meal and lowers the amount of sugar made by your body. This medicine can be used alone or with certain other medicines for diabetes like sulphonylureas, empagliflozin, or insulin. What is type 2 diabetes? Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation.

2. What you need to know before you take jentadueto

Do not take Jentadueto

if you are allergic to linagliptin or metformin or any of the other ingredients of this medicine (listed in section 6).

if you have severely reduced kidney function. if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see Risk of lactic acidosis below) or ketoacidosis. Ketoacidosis is a condition in which substances called ketone bodies accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual fruity smell.

if you ever had a diabetic pre-coma.

if you have a severe infection such as an infection affecting your lung or bronchial system or your kidney. Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see 'Warnings and precautions').

if you have lost a lot of water from your body (dehydration), e.g. due to long-lasting or severe diarrhoea, or if you have vomited several times in a row. Dehydration may lead to kidney problems, which can put you at risk for lactic acidosis (see 'Warnings and precautions').

if you are treated for acute heart failure or have recently had a heart attack, have severe problems with your circulation (such as shock) or have breathing difficulties. This may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis (see 'Warnings and precautions').

if you have liver problems.

if you drink alcohol to excess, either every day or only from time to time (see section 'Jentadueto with alcohol'). Do not take Jentadueto if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine. Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Jentadueto

if you have type 1 diabetes (your body does not produce any insulin). Jentadueto should not be used to treat this condition.

if you are taking insulin or an anti-diabetic medicine known as sulphonylurea , your doctor may want to reduce your dose of insulin or sulphonylurea when you take either of them together with Jentadueto in order to avoid low blood sugar (hypoglycaemia).

if you have or have had a disease of the pancreas. If you have symptoms of acute pancreatitis, like persistent, severe abdominal pain, you should consult your doctor. If you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid. Your doctor may ask you to stop Jentadueto. If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before taking Jentadueto. Diabetic skin problems are a common complication of diabetes. You are advised to follow the recommendations for skin and foot care that you are given by your doctor or nurse. Risk of lactic acidosis. Due to the metformin component, Jentadueto may cause a very rare, but very serious complication called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration(see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease). If any of the above apply to you, talk to your doctor for further instructions. Stop taking Jentadueto for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instruction. Stop taking Jentadueto and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma. Symptoms of lactic acidosis include:

vomiting

stomach ache (abdominal pain)

muscle cramps

a general feeling of not being well with severe tiredness

difficulty in breathing

medicines which increase urine production (diuretics)

medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib)

certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists)

medicines that may change the amount of metformin in your blood, especially if you have reduced kidney function (such as verapamil, rifampicin, cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib, isavuconazole, crizotinib, olaparib).

carbamazepine, phenobarbital or phenytoin. These may be used to control fits (seizures) or chronic pain.

rifampicin. This is an antibiotic used to treat infections such as tuberculosis.

medicines used to treat diseases that involve inflammation, like asthma and arthritis (corticosteroids).

bronchodilators ( -sympathomimetics) for the treatment of bronchial asthma.

alcohol-containing medicines. Jentadueto with alcohol Avoid excessive alcohol intake while taking Jentadueto since this may increase the risk of lactic acidosis (see section Warnings and precautions ). Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not use Jentadueto if you are pregnant. It is unknown if this medicine is harmful to the unborn child. Metformin passes into human milk in small amounts. It is not known whether linagliptin passes into human milk. Talk to your doctor if you want to breast-feed while taking this medicine. Driving and using machines Jentadueto has no or negligible influence on the ability to drive and use machines. However, taking Jentadueto in combination with medicines called sulphonylureas or with insulin can cause too low blood sugar level (hypoglycaemia), which may affect your ability to drive and use machines or work without safe foothold.

3. How to take jentadueto

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. How much to take The amount of Jentadueto that you will take varies depending on your condition and the doses you currently take of metformin and/or individual tablets of linagliptin and metformin. Your doctor will tell you exactly the dose of this medicine to take. How to take this medicine

one tablet twice daily by mouth in the dose prescribed by your doctor.

with meals to lower your chance of an upset stomach. You should not exceed the maximum recommended daily dose of 5 mg linagliptin and 2,000 mg metformin hydrochloride. Continue to take Jentadueto as long as your doctor prescribes it so you can continue to help control your blood sugar. Your doctor may prescribe this medicine together with another oral anti-diabetic medicine or insulin. Remember to take all medicines as directed by your doctor to achieve the best results for your health. You should continue your diet during treatment with Jentadueto and take care that your carbohydrate intake is equally distributed over the day. If you are overweight, continue your energy-restricted diet as instructed. This medicine alone is unlikely to cause abnormally low blood sugar (hypoglycaemia). When Jentadueto is used with a sulphonylurea medicine or with insulin, low blood sugar can occur and your doctor may reduce the dose of your sulphonylurea or insulin. If you take more Jentadueto than you should If you take more Jentadueto tablets than you should have, you may experience lactic acidosis. Symptoms of lactic acidosis are non-specific such as feeling or being very sick, vomiting, stomach ache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. Further symptoms are reduced body temperature and heartbeat. If this happens to you, you may need immediate hospital treatment, as lactic acidosis can lead to coma. Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 2). Take the medicine pack with you. If you forget to take Jentadueto If you forget to take a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. Never take two doses at the same time (morning or evening). If you stop taking Jentadueto Keep taking Jentadueto until your doctor tells you to stop. This is to help keep your blood sugar under control. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Some symptoms need immediate medical attention You should stop taking Jentadueto and see your doctor straight away if you experience the following symptoms of low blood sugar (hypoglycaemia): trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change, or confusion. Hypoglycaemia (frequency very common (may affect more than 1 in 10 people)) is an identified side effect for the combination of Jentadueto plus sulphonylurea and for the combination Jentadueto plus insulin. Jentadueto may cause a very rare (may affect up to 1 user in 10,000), but very serious side effect called lactic acidosis (see section Warnings and precautions ). If this happens you must stop taking Jentadueto and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma. Some patients have experienced inflammation of the pancreas (pancreatitis; frequency rare, may affect up to 1 in 1000 people). STOP taking Jentadueto and contact a doctor immediately if you notice any of the following serious side effects:

Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis). Other side effects of Jentadueto include: Some patients have experienced allergic reactions (frequency rare), which may be serious, including wheezing and shortness of breath (bronchial hyperreactivity; frequency uncommon (may affect up to 1 in 100 people)). Some patients experienced rash (frequency uncommon), hives (urticaria; frequency rare), and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing (angioedema; frequency rare). If you experience any of the signs of illness mentioned above, stop taking Jentadueto and call your doctor right away. Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes. Some patients have had the following side effects while taking Jentadueto:

Common (may affect up to 1 in 10 people): diarrhoea, blood enzyme increase (lipase increase), feeling sick (nausea)

Uncommon: inflamed nose or throat (nasopharyngitis), cough, loss of appetite (decreased appetite), being sick (vomiting), blood enzyme increase (amylase increase), itching (pruritus)

Rare: blistering of skin (bullous pemphigoid) Some patients have experienced the following side effects while taking Jentadueto with insulin

Uncommon: liver function disorders, constipation Side effects when taking metformin alone, that were not described for Jentadueto:

Very common: abdominal pain.

Common (may affect up to 1 in 10 people): a metallic taste (taste disturbance), decreased or low vitamin B12 levels in the blood (symptoms may include extreme tiredness (fatigue), a sore and red tongue (glossitis), pins and needles (paraesthesia) or pale or yellow skin). Your doctor may arrange some tests to find out the cause of your symptoms because some of these may also be caused by diabetes or due to other unrelated health problems.

Very rare (may affect up to 1 in 10,000 people): hepatitis (a problem with your liver), skin reaction as redness of the skin (erythema). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store jentadueto

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister, bottle and carton after EXP. The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions. Blister: Store in the original package in order to protect from moisture. Bottle: Keep the bottle tightly closed in order to protect from moisture. Do not use this medicine if the package is damaged or shows signs of tampering. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Jentadueto contains

The active substances are linagliptin and metformin hydrochloride.

Each Jentadueto 2.5 mg/850 mg film-coated tablet contains 2.5 mg of linagliptin and 850 mg of metformin hydrochloride.

Each Jentadueto 2.5 mg/1,000 mg film-coated tablet contains 2.5 mg of linagliptin and 1,000 mg of metformin hydrochloride.

The other ingredients are:

Tablet core: arginine, copovidone, magnesium stearate, maize starch, silica, colloidal anhydrous.

Film coating: hypromellose, titanium dioxide (E171), talc, propylene glycol. Jentadueto 2.5 mg/850 mg film-coated tablets also contains iron oxide red (E172) and iron oxide yellow (E172). Jentadueto 2.5 mg/1,000 mg film-coated tablets also contains iron oxide red (E172). What Jentadueto looks like and contents of the pack Jentadueto 2.5 mg/850 mg are oval, biconvex, light orange, film-coated tablets (tablets). They have "D2/850" debossed on one side and the Boehringer Ingelheim logo debossed on the other. Jentadueto 2.5 mg/1,000 mg are oval, biconvex light pink film-coated tablets (tablets). They have "D2/1000" debossed on one side and the Boehringer Ingelheim logo debossed on the other. Jentadueto is available in perforated unit dose blisters with 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets and multipacks containing 120 x 1 (2 packs of 60 x 1), 180 x 1 (2 packs of 90 x 1), 180 x 1 (3 packs of 60 x 1) and 200 x 1 (2 packs of 100 x 1) film-coated tablets. Jentadueto is also available in plastic bottles with plastic screw cap and a silica gel desiccant. Bottles contain 14, 60 or 180 film-coated tablets. Not all pack sizes may be marketed in your country. Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Strasse 55216 Ingelheim am Rhein Germany Manufacturer Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 55216 Ingelheim am Rhein Germany Boehringer Ingelheim Hellas Single Member S.A. 5th km Paiania Markopoulo Koropi Attiki, 19Greece Dragenopharm Apotheker P schl GmbH G llstra e 1 84529 Tittmoning Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien Boehringer Ingelheim SComm T l/Tel: +32 2 773 33 Lietuva Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas Tel: +370 5 2595 . -

: +359 2 958 79 Luxembourg/Luxemburg Boehringer Ingelheim SComm T l/Tel: +32 2 773 33 esk republika Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 Magyarorsz g Boehringer Ingelheim RCV GmbH & Co KG Magyarorsz gi Fi ktelepe Tel: +36 1 299 8Danmark Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9Deutschland Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 Nederland Boehringer Ingelheim b.v. Tel: +31 (0) 800 22 55 Eesti Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal Tel: +372 612 8Norge Boehringer Ingelheim Norway KS Tlf: +47 66 76 13
Boehringer Ingelheim . . T : +30 2 10 89 06 sterreich Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7Espa a Boehringer Ingelheim Espa a, S.A. Tel: +34 93 404 51 Polska Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 France Boehringer Ingelheim France S.A.S. T l: +33 3 26 50 45 Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 Hrvatska Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 Rom nia Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucure ti Tel: +40 21 302 2Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9Slovenija Boehringer Ingelheim RCV GmbH & Co KG Podru nica Ljubljana Tel: +386 1 586 40 sland Vistor hf. S mi: +354 535 7Slovensk republika Boehringer Ingelheim RCV GmbH & Co KG organiza n zlo ka Tel: +421 2 5810 1Italia Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 Suomi/Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102
Boehringer Ingelheim . . T : +30 2 10 89 06 Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 Latvija Boehringer Ingelheim RCV GmbH & Co KG Latvijas fili le Tel: +371 67 240 United Kingdom (Northern Ireland) Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9This leaflet was last revised in {MM/YYYY} Detailed information on this medicine is available on the European Medicines Agency web site:


Additional Resources Included in Document


Entry 1 - fullUrl = Composition/composition-en-dea6bb992c7a311f66506a0f31878b7e

Resource Composition:

Generated Narrative: Composition composition-en-dea6bb992c7a311f66506a0f31878b7e

Language: en

Profile: Composition (ePI)

identifier: http://ema.europa.eu/identifier/EU/1/12/780/001 (10 x 1 film-coated tablets)

status: Final

type: Package Leaflet

category: Raw

date: 2022-02-16 13:28:17+0000

author: Organization ACME industry

title: TEST PURPOSES ONLY - jentadueto

Attesters

-ModeTime
*Official2022-02-16 13:28:17+0000

Entry 2 - fullUrl = MedicinalProductDefinition/mpdea6bb992c7a311f66506a0f31878b7e

Resource MedicinalProductDefinition:

Generated Narrative: MedicinalProductDefinition mpdea6bb992c7a311f66506a0f31878b7e

identifier: http://ema.europa.eu/identifier/EU/1/12/780/001 (10 x 1 film-coated tablets)

type: Medicinal Product

domain: Human use

status: active

legalStatusOfSupply: Medicinal product subject to medical prescription

name

productName: Jentadueto 2.5 mg/850 mg film-coated tablets

type: Full name

part

part: nan

type: Invented name part

part

part: nan

type: Scientific name part

part

part: nan

type: Strength part

part

part: nan

type: Pharmaceutical dose form part

Usages

-CountryJurisdictionLanguage
*EUEUen